- NZ$8.05m
- NZ$8.61m
- NZ$1.51m
- 11
- 41
- 50
- 24
Annual balance sheet for Rua Bioscience, fiscal year end - June 30th, NZD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 16.4 | 9.94 | 4.56 | 0.895 | 0.241 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.606 | 1.07 | 0.863 | 0.277 | 0.367 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 17.1 | 11.4 | 5.6 | 2.82 | 2.31 |
| Net Property, Plant And Equipment | 7.1 | 6.64 | 4.54 | 2.65 | 2.21 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 30.9 | 33.6 | 21 | 7.74 | 6.78 |
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.18 | 4.86 | 0.762 | 0.874 | 1.85 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 2.02 | 9.38 | 0.83 | 0.973 | 1.89 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 28.8 | 24.2 | 20.1 | 6.77 | 4.89 |
| Total Liabilities & Shareholders' Equity | 30.9 | 33.6 | 21 | 7.74 | 6.78 |
| Total Common Shares Outstanding |